Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated ...

A recent prospective study highlights the substantial burden of late RT-related genitourinary complications among men with ...

Of all the health conditions facing men as they get older, there is no doubt that prostate cancer is the most widely ...

Super Bowl ad puts male reproduction gland in the spotlight. But is that specific prostate test the best method based on experts' recommendation?

A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now ...

These results suggest that oxybutynin may offer a practical and effective option for managing ADT-associated hot flashes in ...

The Food and Drug Administration recently approved the IsoPSA blood test, which was developed by Cleveland Diagnostics, a ...

Prostate cancer is the most common cancer diagnosis in men, accounting for 30% of male cancers.

Metastasis-directed therapy for oligometastatic prostate cancer was associated with improved outcomes in a systematic review and meta-analysis.

What key experiences or clinical gaps motivated your focus on advancing prostate cancer diagnostics, particularly MRI-led ...

A new study from The University of Texas MD Anderson Cancer Center has found that treating prostate cancer early, before it spreads widely, can make a big difference. The research, published in The ...

Metastasis-directed therapy (MDT) delivered via stereotactic body radiotherapy has gained substantial attention over the past decade. Landmark trials such as STOMP1 and ORIOLE2 fundamentally shifted ...